Pfizer Reports Third-Quarter 2012 Results

BY Business Wire | 11/01/12 - 07:00 AM EDT

Stock quotes in this article: PFE

Comment

Find out if (PFE) is in Cramer's Portfolio.

“With regard to our innovative core, I am very pleased with the recent U.S. Food and Drug Administration approval of Bosulif (bosutinib) for chronic myelogenous leukemia, as well as approval of Inlyta (axitinib) for advanced renal cell carcinoma and conditional marketing authorization of Xalkori (critzotinib) for advanced non-small cell lung cancer, both in the EU. I also look forward to regulatory action for tofacitinib in moderate-to-severe rheumatoid arthritis and Eliquis (apixaban) in atrial fibrillation in the U.S., EU and Japan as well as Bosulif in key international markets.”

“Additionally, we filed a registration statement with the Securities and Exchange Commission for the potential initial public offering of a minority stake in our Animal Health business, Zoetis. Given our demonstrated ability to advance our strategic initiatives, I believe we are well-positioned to deliver attractive returns for our shareholders over time,” Mr. Read concluded.

Frank D’Amelio, Chief Financial Officer, stated, “Given our financial performance to date, we are narrowing the ranges for certain components of our 2012 financial guidance. Further, the Board of Directors has authorized a new $10 billion share repurchase program to be utilized over time, upon the sale of the Nutrition ⁽¹⁾ business to Nestlé, which we now expect to close in the next few months. This new program is in addition to the $4.1 billion authorization remaining under our current share repurchase program. So far this year, we have repurchased approximately $5.9 billion, or 255.1 million shares, of our common stock.”

2012 Financial Guidance ⁽⁷⁾

Pfizer’s financial guidance, at current exchange rates ⁽⁸⁾, is summarized below. Since the Nutrition ⁽¹⁾ business is presented as a discontinued operation, the full-year results of that business only impact the Reported Diluted EPS ⁽³⁾ and operating cash flow components of our 2012 financial guidance.


Reported Revenues				$58.0 to $59.0 billion (previously $58.0 to $60.0 billion)
Adjusted Cost of Sales ⁽²⁾ as a Percentage of Revenues				18.7% to 19.2% (previously 19.5% to 20.5%)
Adjusted SI&A Expenses ⁽²⁾				$16.3 to $16.8 billion (previously $16.3 to $17.3 billion)
Adjusted R&D Expenses ⁽²⁾				$7.0 to $7.25 billion (previously $6.75 to $7.25 billion)
Adjusted Other (Income)/Deductions ⁽²⁾				Approximately $900 million (previously approximately $1.0 billion)
Effective Tax Rate on Adjusted Income ⁽²⁾				Approximately 29%
Reported Diluted EPS ⁽³⁾				$1.30 to $1.38 (previously $1.21 to $1.36)
Adjusted Diluted EPS ⁽²⁾				$2.14 to $2.17 (previously $2.12 to $2.22)
Operating Cash Flow				Approximately $18.5 billion (previously approximately $19.0 billion)

For additional details, please see the attached financial schedules, product revenue tables, supplemental information and disclosure notice.

(1)				On April 23, 2012, Pfizer announced that it entered into an agreement to sell the Nutrition business to Nestlé. The transaction is expected to close in the next few months, assuming the receipt of the required regulatory clearances and the satisfaction of other closing conditions. As a result of Pfizer’s decision to divest this business, the operating results of the Nutrition business are reported as Discontinued Operations – net of tax in the consolidated statements of income for all periods.

(2)				"Adjusted Income" and its components and "Adjusted Diluted Earnings Per Share (EPS)" are defined as reported U.S. generally accepted accounting principles (GAAP) net income ⁽³⁾ and its components and reported diluted EPS ⁽³⁾ excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. Adjusted Cost of Sales, Adjusted Selling, Informational and Administrative (SI&A) expenses, Adjusted Research and Development (R&D) expenses and Adjusted Other (Income)/Deductions are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. As described under Adjusted Income in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of Pfizer's Form 10-Q for the fiscal quarter ended July 1, 2012, management uses adjusted income, among other factors, to set performance goals and to measure the performance of the overall company. We believe that investors' understanding of our performance is enhanced by disclosing this measure. Reconciliations of certain GAAP reported to non-GAAP adjusted information for the third quarter and first nine months of 2012 and 2011, as well as reconciliations of full-year 2012 guidance for adjusted income and adjusted diluted EPS to full-year 2012 guidance for reported net income ⁽³⁾ and reported diluted EPS ⁽³⁾, are provided in the materials accompanying this report. The adjusted income and its components and adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.

(3)				“Reported Net Income” is defined as net income attributable to Pfizer Inc. in accordance with U.S. GAAP. “Reported Diluted EPS” is defined as reported diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.

(4)				On August 1, 2011, Pfizer completed the sale of Capsugel to an affiliate of Kohlberg Kravis Roberts & Co. L.P. The operating results associated with Capsugel and the gain on the sale of Capsugel are reported as Discontinued operations – net of tax in the consolidated statements of income for the three and nine months ended October 2, 2011. Additionally, due to the acquisition of King Pharmaceuticals, Inc. (King), legacy King operations are reflected in the results beginning January 31, 2011. Therefore, in accordance with Pfizer’s domestic and international reporting periods, the operating results for the first nine months of 2011 reflect approximately eight months of King’s U.S. operations and approximately seven months of King’s international operations.

(5)				For a description of each business unit, see Note 13A to Pfizer’s condensed consolidated financial statements included in Pfizer’s Form 10-Q for the fiscal quarter ended July 1, 2012.

(6)				Other includes revenues generated primarily from Pfizer CentreSource, Pfizer’s contract manufacturing and bulk pharmaceutical chemical sales organization.

(7)				The 2012 financial guidance includes the revenues and expenses related to the Nutrition business, which is reflected as a discontinued operation, but does not include the gain on the pending sale of the Nutrition business. Does not assume the completion of any business-development transactions not completed as of September 30, 2012, including any one-time upfront payments associated with such transactions. Also excludes the potential effects of the resolution of litigation-related matters not substantially resolved as of September 30, 2012, except for charges for such matters that have been recorded during the first nine months of 2012.

(8)				The current exchange rates assumed in connection with the 2012 financial guidance are a blend of the actual exchange rates in effect during the first nine months of 2012 and the mid-October 2012 exchange rates for the remainder of the year.


PFIZER INC. AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME ^(a)
(UNAUDITED)
(millions, except per common share data)

	Third Quarter					% Incr. /	Nine Months				% Incr. /
	2012			2011		(Decr.)	2012		2011		(Decr.)
Revenues	$	13,976		$	16,609	(16)	$	43,918	$	49,118	(11)
Costs and expenses:
Cost of sales ^(b)		2,665			3,409	(22)		8,162		10,449	(22)
Selling, informational and administrative expenses ^(b)		3,847			4,457	(14)		11,801		13,635	(13)
Research and development expenses ^(b)		1,981			2,176	(9)		5,734		6,487	(12)
Amortization of intangible assets ^(c)		1,228			1,389	(12)		3,939		4,138	(5)
Restructuring charges and certain acquisition-related costs		302			1,090	(72)		1,089		2,458	(56)
Other deductions--net		962			547	76		3,283		1,802	82
Income from continuing operations before provision/(benefit) for taxes on income		2,991			3,541	(16)		9,910		10,149	(2)
Provision/(benefit) for taxes on income		(119	)		1,216	(110)		1,882		3,167	(41)
Income from continuing operations		3,110			2,325	34		8,028		6,982	15
Discontinued operations:
Income from discontinued operations--net of tax		104			96	8		249		303	(18)
Gain on sale of discontinued operations--net of tax		-			1,328	(100)		-		1,316	(100)
Discontinued operations--net of tax		104			1,424	(93)		249		1,619	(85)
Net income before allocation to noncontrolling interests		3,214			3,749	(14)		8,277		8,601	(4)
Less: Net income attributable to noncontrolling interests		6			11	(45)		22		31	(29)
Net income attributable to Pfizer Inc.	$	3,208		$	3,738	(14)	$	8,255	$	8,570	(4)
Earnings per common share--basic: ^(d)
Income from continuing operations attributable to Pfizer Inc. common shareholders	$	0.42		$	0.30	40	$	1.07	$	0.88	22
Discontinued operations--net of tax		0.01			0.18	(94)		0.03		0.21	(86)
Net income attributable to Pfizer Inc. common shareholders	$	0.43		$	0.48	(10)	$	1.10	$	1.09	1
Earnings per common share--diluted: ^(d)
Income from continuing operations attributable to Pfizer Inc. common shareholders	$	0.41		$	0.30	37	$	1.06	$	0.88	20
Discontinued operations--net of tax		0.01			0.18	(94)		0.03		0.20	(85)
Net income attributable to Pfizer Inc. common shareholders	$	0.43		$	0.48	(10)	$	1.09	$	1.08	1
Weighted-average shares used to calculate earnings per common share:
Basic		7,436			7,770			7,483		7,877
Diluted		7,508			7,810			7,550		7,925

(a)		The above financial statements present the three and nine months ended September 30, 2012 and October 2, 2011. Subsidiaries operating outside the United States are included for the three and nine months ended August 26, 2012 and August 28, 2011.

		Beginning in the second quarter of 2012, as a result of our decision to sell the Nutrition business, we report the operating results of the Nutrition business as Discontinued operations: Income from discontinued operations--net of tax for all periods presented.

		On August 1, 2011, we completed the sale of our Capsugel business and recognized a gain on the sale in Discontinued operations: Gain on sale of discontinued operations--net of tax for the three and nine months ended October 2, 2011. The operating results of this business are reported as Discontinued operations: Income from discontinued operations--net of tax for the three and nine months ended October 2, 2011.


		On January 31, 2011, we completed a tender offer for the outstanding shares of common stock of King Pharmaceuticals, Inc. (King) and, commencing from that date, our financial statements include the assets, liabilities, operating results and cash flows of King. As a result, and in accordance with our domestic and international reporting periods, our operating results for the nine months ended October 2, 2011 reflect approximately eight months of King’s U.S. operations and approximately seven months of King’s international operations.

		Certain amounts and percentages may reflect rounding adjustments.

		See Supplemental Information that accompanies these materials for additional details.

		The financial results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results which could ultimately be achieved for the full year.

(b)		Exclusive of amortization of intangible assets, except as discussed in footnote (c) below.

(c)		Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate.

(d)		EPS amounts may not add due to rounding.


PFIZER INC. AND SUBSIDIARY COMPANIES
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per common share data)

		Quarter Ended September 30, 2012
					PurchaseAccountingAdjustments			Acquisition-RelatedCosts ⁽²⁾						CertainSignificantItems ⁽³⁾		Non-GAAPAdjusted ^(a)
		GAAP Reported ⁽¹⁾									DiscontinuedOperations
		GAAP Reported ⁽¹⁾									DiscontinuedOperations
Revenues	$	13,976		$	-		$	-		$	-		$	-			$	13,976
Cost of sales ^(b)		2,665			2			(78	)		-			(24	)			2,565
Selling, informational and administrative expenses ^(b)		3,847			(2	)		(3	)		-			(113	)			3,729
Research and development expenses ^(b)		1,981			1			-			-			(47	)			1,935
Amortization of intangible assets ^(c)		1,228			(1,186	)		-			-			-				42
Restructuring charges and certain acquisition-related costs		302			-			(149	)		-			(153	)			-
Other deductions--net		962			45			-			-			(821	)			186
Income from continuing operations before provision/(benefit) for taxes on income		2,991			1,140			230			-			1,158				5,519
Provision/(benefit) for taxes on income		(119	)		327			40			-			1,316				1,564
Income from continuing operations		3,110			813			190			-			(158	)			3,955
Discontinued operations--net of tax		104			-			-			(104	)		-				-
Net income attributable to noncontrolling interests		6			-			-			-			-				6
Net income attributable to Pfizer Inc.		3,208			813			190			(104	)		(158	)			3,949
Earnings per common share attributable to Pfizer Inc.--diluted ^(d)		0.43			0.11			0.03			(0.01	)		(0.02	)			0.53




		Nine Months Ended September 30, 2012
					Purchase			Acquisition-						Certain
		GAAP			Accounting			Related			Discontinued			Significant				Non-GAAP
		Reported ⁽¹⁾			Adjustments			Costs ⁽²⁾			Operations			Items ⁽³⁾				Adjusted ^(a)
Revenues	$	43,918		$	-		$	-		$	-		$	-			$	43,918
Cost of sales ^(b)		8,162			(9	)		(214	)		-			(51	)			7,888
Selling, informational and administrative expenses ^(b)		11,801			4			(8	)		-			(174	)			11,623
Research and development expenses ^(b)		5,734			3			(5	)		-			(386	)			5,346
Amortization of intangible assets ^(c)		3,939			(3,763	)		-			-			-				176
Restructuring charges and certain acquisition-related costs		1,089			-			(423	)		-			(666	)			-
Other deductions--net		3,283			15			-			-			(2,644	)			654
Income from continuing operations before provision/(benefit) for taxes on income		9,910			3,750			650			-			3,921				18,231
Provision/(benefit) for taxes on income		1,882			1,025			161			-			2,177				5,245
Income from continuing operations		8,028			2,725			489			-			1,744				12,986
Discontinued operations--net of tax		249			-			-			(249	)		-				-
Net income attributable to noncontrolling interests		22			-			-			-			-				22
Net income attributable to Pfizer Inc.		8,255			2,725			489			(249	)		1,744				12,964
Earnings per common share attributable to Pfizer Inc.--diluted ^(d)		1.09			0.36			0.06			(0.03	)		0.23				1.72

(a)		Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are Non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

(b)		Exclusive of amortization of intangible assets, except as discussed in footnote (c) below.

(c)		Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate.

(d)		EPS amounts may not add due to rounding.

See end of tables for notes (1), (2) and (3).

Certain amounts may reflect rounding adjustments.


PFIZER INC. AND SUBSIDIARY COMPANIES
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per common share data)

		Quarter Ended October 2, 2011
				Purchase			Acquisition-						Certain
		GAAP		Accounting			Related			Discontinued			Significant			Non-GAAP
		Reported ⁽¹⁾		Adjustments			Costs ⁽²⁾			Operations			Items ⁽³⁾			Adjusted ^(a)
Revenues	$	16,609	$	-		$	-		$	-		$	-		$	16,609
Cost of sales ^(b)		3,409		(286	)		(68	)		-			2			3,057
Selling, informational and administrative expenses ^(b)		4,457		(9	)		(18	)		-			(33	)		4,397
Research and development expenses ^(b)		2,176		3			(6	)		-			(150	)		2,023
Amortization of intangible assets ^(c)		1,389		(1,352	)		-			-			-			37
Restructuring charges and certain acquisition-related costs		1,090		-			(202	)		-			(888	)		-
Other deductions--net		547		(53	)		-			-			(240	)		254
Income from continuing operations before provision/(benefit) for taxes on income		3,541		1,697			294			-			1,309			6,841
Provision/(benefit) for taxes on income		1,216		445			54			-			419			2,134
Income from continuing operations		2,325		1,252			240			-			890			4,707
Discontinued operations--net of tax ^(d)		1,424		-			-			(1,424	)		-			-
Net income attributable to noncontrolling interests		11		-			-			-			-			11
Net income attributable to Pfizer Inc.		3,738		1,252			240			(1,424	)		890			4,696
Earnings per common share attributable to Pfizer Inc.--diluted ^(e)		0.48		0.16			0.03			(0.18	)		0.11			0.60




		Nine Months Ended October 2, 2011
				PurchaseAccountingAdjustments			Acquisition-RelatedCosts ⁽²⁾						CertainSignificantItems ⁽³⁾
		GAAP Reported ⁽¹⁾								DiscontinuedOperations						Non-GAAPAdjusted ^(a)
		GAAP Reported ⁽¹⁾								DiscontinuedOperations						Non-GAAPAdjusted ^(a)
Revenues	$	49,118	$	-		$	-		$	-		$	-		$	49,118
Cost of sales ^(b)		10,449		(1,081	)		(410	)		-			(7	)		8,951
Selling, informational and administrative expenses ^(b)		13,635		(6	)		(41	)		-			(39	)		13,549
Research and development expenses ^(b)		6,487		-			(9	)		-			(398	)		6,080
Amortization of intangible assets ^(c)		4,138		(4,039	)		-			-			-			99
Restructuring charges and certain acquisition-related costs		2,458		-			(996	)		-			(1,462	)		-
Other deductions--net		1,802		(71	)		-			-			(1,269	)		462
Income from continuing operations before provision/(benefit) for taxes on income		10,149		5,197			1,456			-			3,175			19,977
Provision/(benefit) for taxes on income		3,167		1,345			320			-			1,059			5,891
Income from continuing operations		6,982		3,852			1,136			-			2,116			14,086
Discontinued operations--net of tax ^(d)		1,619		-			-			(1,619	)		-			-
Net income attributable to noncontrolling interests		31		-			-			-			-			31
Net income attributable to Pfizer Inc.		8,570		3,852			1,136			(1,619	)		2,116			14,055
Earnings per common share attributable to Pfizer Inc.--diluted ^(e)		1.08		0.49			0.14			(0.20	)		0.27			1.77

(a)		Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are Non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

(b)		Exclusive of amortization of intangible assets, except as discussed in footnote (c) below.

(c)		Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate.




(d)		On August 1, 2011, we completed the sale of our Capsugel business. The gain recognized related to the sale of this business, as well as the operating results of this business, are included in GAAP Reported Discontinued operations—net of tax.

(e)		EPS amounts may not add due to rounding.

See end of tables for notes (1), (2) and (3).

Certain amounts may reflect rounding adjustments.


PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS*
(UNAUDITED)

1)		The financial statements present the three and nine months ended September 30, 2012 and October 2, 2011. Subsidiaries operating outside the United States are included for the three and nine months ended August 26, 2012 and August 28, 2011.

		Beginning in the second quarter of 2012, as a result of our decision to sell the Nutrition business, we report the operating results of the Nutrition business as Discontinued operations: Income from discontinued operations--net of tax for all periods presented.

		On August 1, 2011, we completed the sale of our Capsugel business and recognized a gain on the sale in Discontinued operations: Gain on sale of discontinued operations--net of tax for the three and nine months ended October 2, 2011. The operating results of this business are reported as Discontinued operations: Income from discontinued operations--net of tax for the three and nine months ended October 2, 2011.


		On January 31, 2011, we completed a tender offer for the outstanding shares of common stock of King Pharmaceuticals, Inc. (King) and, commencing from that date, our financial statements include the assets, liabilities, operating results and cash flows of King. As a result, and in accordance with our domestic and international reporting periods, our operating results for the nine months ended October 2, 2011 reflect approximately eight months of King’s U.S. operations and approximately seven months of King’s international operations.

2)		Acquisition-related costs include the following:

	Third Quarter						Nine Months
(millions of dollars)	2012			2011			2012			2011

Transaction costs ^(a)	$	-		$	5		$	1		$	28
Integration costs ^(a)		87			184			295			562
Restructuring charges ^(a)		62			13			127			406
Additional depreciation--asset restructuring ^(b)		81			92			227			460
Total acquisition-related costs--pre-tax		230			294			650			1,456
Income taxes ^(c)		(40	)		(54	)		(161	)		(320	)
Total acquisition-related costs--net of tax	$	190		$	240		$	489		$	1,136

	(a)		Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. Restructuring charges include employee termination costs, asset impairments and other exit costs associated with business combinations. The sum of these costs and charges is included in Restructuring charges and certain acquisition-related costs.

	(b)		Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions. Included in Cost of sales ($78 million) and Selling, informational and administrative expenses ($3 million) for the three months ended September 30, 2012. Included in Cost of sales ($214 million), Selling, informational and administrative expenses ($8 million) and Research and development expenses ($5 million) for the nine months ended September 30, 2012. Included in Cost of sales ($68 million), Selling, informational and administrative expenses ($18 million) and Research and development expenses ($6 million) for the three months ended October 2, 2011. Included in Cost of sales ($410 million) , Selling, informational and administrative expenses ($41 million) and Research and development expenses ($9 million) for the nine months ended October 2, 2011.


	(c)		Included in Provision/(benefit) for taxes on income.


3	)	Certain significant items include the following:
				Third Quarter						Nine Months
			(millions of dollars)	2012			2011			2012			2011

			Restructuring charges ^(a)	$	153		$	888		$	666		$	1,462
			Implementation costs and additional depreciation--asset restructuring ^(b)		111			183			486			437
			Certain legal matters ^(c)		725			132			1,983			657
			Certain asset impairment charges ^(d)		54			106			543			595
			Costs associated with the potential separation of the Animal Health business ^(e)		100			8			191			8
			Other		15			(8	)		52			16
			Total certain significant items--pre-tax		1,158			1,309			3,921			3,175
			Income taxes ^(f)		(1,316	)		(419	)		(2,177	)		(1,059	)
			Total certain significant items--net of tax	$	(158	)	$	890		$	1,744		$	2,116

	(a)		Included in Restructuring charges and certain acquisition-related costs, primarily related to our cost-reduction and productivity initiatives.

	(b)		Primarily related to our cost-reduction and productivity initiatives. Included in Cost of Sales ($19 million), Selling, informational and administrative expenses ($45 million) and Research and development expenses ($47 million) for the three months ended September 30, 2012. Included in Cost of Sales ($23 million), Selling, informational and administrative expenses ($77 million) and Research and development expenses ($386 million) for the nine months ended September 30, 2012. Included in Selling, informational and administrative expenses ($33 million) and Research and development expenses ($150 million) for the three months ended October 2, 2011. Included in Selling, informational and administrative expenses ($39 million) and Research and development expenses ($398 million) for the nine months ended October 2, 2011.

	(c)		Included in Other deductions--net. In the third quarter of 2012, primarily includes a $491 million charge resulting from an agreement-in-principle with the U.S. Department of Justice to resolve an investigation into Wyeth’s historical promotional practices in connection with Rapamune. In the first nine months of 2012, primarily includes the aforementioned $491 million charge related to Rapamune, a $450 million settlement of a lawsuit by Brigham Young University related to Celebrex, and charges for hormone-replacement therapy litigation. In 2011, primarily includes charges for hormone-replacement therapy litigation.

	(d)		Primarily included in Other deductions--net. In the first nine months of 2012, primarily includes certain intangible assets acquired in connection with our acquisitions of Wyeth and King, including in-process research and development (IPR&D) intangible assets. In the third quarter and first nine months of 2011, primarily includes certain intangible assets acquired in connection with our acquisition of Wyeth, including IPR&D intangible assets.

	(e)		Costs incurred in connection with the potential initial public offering of a minority stake in our Animal Health business, Zoetis, Inc. Includes expenditures for banking, legal, accounting and similar services related to the potential transaction, as well as costs incurred associated with the potential separation of Animal Health employees, net assets and activities from Pfizer, such as consulting and systems costs. Included in Selling, informational and administrative expenses ($68 million) and Other deductions--net ($32 million) for the three months ended September 30, 2012. Included in Selling, informational and administrative expenses ($98 million) and Other deductions--net ($93 million) for the nine months ended September 30, 2012. Included in Selling, informational and administrative expenses for the three and nine months ended October 2, 2011.

	(f)		Included in Provision/(benefit) for taxes on income. Includes a settlement with the U.S. IRS related to audits for multiple tax years that favorably impacted GAAP Reported net income by $1.1 billion, representing tax and interest, for the three and nine months ended September 30, 2012.

Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are Non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.


PFIZER INC.
BUSINESS REVENUES ⁽¹⁾
FIRST NINE MONTHS OF 2012 AND 2011
(UNAUDITED)
(millions of dollars)



	2012		2011		Change		ForeignExchange		Operational
Primary Care	$	11,725	$	17,259	(32	%)	(1	%)	(31	%)
Specialty Care		10,483		11,425	(8	%)	(2	%)	(6	%)
Established Products		7,865		6,914	14	%	(2	%)	16	%
Emerging Markets		7,308		7,031	4	%	(6	%)	10	%
Oncology		940		982	(4	%)	(3	%)	(1	%)
Biopharmaceutical		38,321		43,611	(12	%)	(2	%)	(10	%)

Animal Health		3,128		3,078	2	%	(4	%)	6	%
Consumer Healthcare		2,276		2,218	3	%	(2	%)	5	%
Other		193		211	(9	%)	(1	%)	(8	%)

Total	$	43,918	$	49,118	(11	%)	(2	%)	(9	%)

(1)

For a description of each business unit, see Note 13A to Pfizer's condensed consolidated financial statements included in Pfizer's Form 10-Q for the fiscal quarter ended July 1, 2012.


PFIZER INC.
ADJUSTED SELECTED COSTS AND EXPENSES ⁽¹⁾
FIRST NINE MONTHS OF 2012 AND 2011
(UNAUDITED)




($ in millions)(Favorable)/Unfavorable	2012		2011		% Change	ForeignExchange	Operational

Adjusted Cost of Sales ⁽¹⁾	$	7,888	$	8,951	(12%)	(8%)	(4%)
As a Percent of Revenues		18.0%		18.2%	N/A	N/A	N/A
Adjusted SI&A Expenses ⁽¹⁾		11,623		13,549	(14%)	(2%)	(12%)
Adjusted R&D Expenses ⁽¹⁾		5,346		6,080	(12%)	(1%)	(11%)

Total	$	24,857	$	28,580	(13%)	(4%)	(9%)

(1) Adjusted cost of sales, Adjusted selling, informational and administrative (SI&A) expenses and Adjusted research and development (R&D) expenses are defined as the corresponding reported U.S. generally accepted accounting principles (GAAP) income statement line items excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. Reconciliations of certain GAAP reported to non-GAAP adjusted information for the third quarter and first nine months of 2012 and 2011 are provided in the materials accompanying this report. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items.


PFIZER INC. REVENUES THIRD QUARTER 2012 and 2011 (UNAUDITED) (millions of dollars)

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)

	2012	2011	% Change		2012	2011	% Change	2012	2011	% Change
			Total	Oper.			Total			Total	Oper.
TOTAL REVENUES	$13,976	$16,609	(16%)	(12%)	$5,627	$6,879	(18%)	$8,349	$9,730	(14%)	(7%)
REVENUES FROM BIOPHARMACEUTICAL PRODUCTS:	$12,117	$14,747	(18%)	(14%)	$4,769	$6,019	(21%)	$7,348	$8,728	(16%)	(9%)
Lipitor ^(b)	749	2,602	(71%)	(70%)	192	1,470	(87%)	557	1,132	(51%)	(48%)
Lyrica	1,036	961	8%	14%	430	379	13%	606	582	4%	14%
Enbrel (Outside the U.S. and Canada)	893	957	(7%)	4%	-	-	-	893	957	(7%)	4%
Prevnar 13/Prevenar 13	868	1,006	(14%)	(12%)	440	454	(3%)	428	552	(22%)	(19%)
Celebrex	676	643	5%	7%	438	405	8%	238	238	-	6%
Viagra	517	493	5%	9%	287	244	18%	230	249	(8%)	-
Norvasc	319	350	(9%)	(6%)	13	5	160%	306	345	(11%)	(9%)
Zyvox	328	321	2%	7%	158	154	3%	170	167	2%	11%
Sutent	294	298	(1%)	7%	82	78	5%	212	220	(4%)	7%
Premarin family	262	267	(2%)	(1%)	237	241	(2%)	25	26	(4%)	3%
Genotropin	212	215	(1%)	5%	59	46	28%	153	169	(9%)	(2%)
Xalatan/Xalacom	181	277	(35%)	(29%)	9	9	-	172	268	(36%)	(31%)
BeneFIX	201	178	13%	18%	96	76	26%	105	102	3%	12%
Detrol/Detrol LA	176	213	(17%)	(15%)	112	136	(18%)	64	77	(17%)	(10%)
Vfend	187	171	9%	17%	21	-	100%	166	171	(3%)	3%
Chantix/Champix	146	156	(6%)	(3%)	62	68	(9%)	84	88	(5%)	1%
Pristiq	152	146	4%	6%	120	119	1%	32	27	19%	32%
Refacto AF/Xyntha	150	140	7%	17%	28	32	(13%)	122	108	13%	25%
Revatio	135	140	(4%)	1%	78	80	(3%)	57	60	(5%)	6%
Zoloft	129	139	(7%)	(3%)	17	15	13%	112	124	(10%)	(5%)
Medrol	113	127	(11%)	(7%)	24	33	(27%)	89	94	(5%)	1%
Zosyn/Tazocin	109	149	(27%)	(24%)	39	75	(48%)	70	74	(5%)	1%
Effexor	107	165	(35%)	(31%)	37	52	(29%)	70	113	(38%)	(31%)
Geodon/Zeldox	57	263	(78%)	(76%)	26	217	(88%)	31	46	(33%)	(21%)
Zithromax/Zmax	89	93	(4%)	(1%)	3	4	(25%)	86	89	(3%)	1%
Prevnar/Prevenar (7-valent)	81	98	(17%)	10%	-	-	-	81	98	(17%)	10%
Fragmin	91	95	(4%)	4%	11	9	22%	80	86	(7%)	3%
Relpax	92	86	7%	11%	56	47	19%	36	39	(8%)	2%
Rapamune	92	96	(4%)	1%	49	47	4%	43	49	(12%)	(2%)
Cardura	79	92	(14%)	(9%)	2	1	100%	77	91	(15%)	(9%)
Aricept ^(c)	71	117	(39%)	(34%)	-	-	-	71	117	(39%)	(34%)
Tygacil	82	76	8%	15%	37	38	(3%)	45	38	18%	34%
EpiPen	67	59	14%	14%	52	47	11%	15	12	25%	23%
Xanax XR	66	77	(14%)	(6%)	13	13	-	53	64	(17%)	(7%)
BMP2	58	83	(30%)	(30%)	58	77	(25%)	-	6	(100%)	(100%)
Caduet	68	150	(55%)	(53%)	13	80	(84%)	55	70	(21%)	(16%)
Sulperazon	62	51	22%	22%	-	-	-	62	51	22%	22%
Diflucan	61	72	(15%)	(9%)	1	-	100%	60	72	(17%)	(11%)
Dalacin/Cleocin	74	51	45%	50%	40	15	167%	34	36	(6%)	(1%)
Neurontin	52	67	(22%)	(18%)	12	14	(14%)	40	53	(25%)	(17%)
Unasyn	54	58	(7%)	(3%)	-	3	(100%)	54	55	(2%)	1%
Aromasin	51	85	(40%)	(36%)	3	8	(63%)	48	77	(38%)	(34%)
Arthrotec	50	61	(18%)	(15%)	28	32	(13%)	22	29	(24%)	(19%)
Inspra	51	51	-	12%	1	1	-	50	50	-	13%
Toviaz	52	49	6%	10%	29	26	12%	23	23	-	8%
Metaxalone/Skelaxin	55	57	(4%)	(5%)	55	57	(4%)	-	-	-	-
Methotrexate	50	51	(2%)	5%	-	-	-	50	51	(2%)	5%
Protonix	50	65	(23%)	(23%)	50	65	(23%)	-	-	-	-
Alliance Revenue ^(d)	879	919	(4%)	(3%)	687	571	20%	192	348	(45%)	(42%)
All other biopharmaceutical products	1,643	1,611	2%	8%	564	476	18%	1,079	1,135	(5%)	3%
All other established products ^(e)	1,407	1,406	-	6%	453	388	17%	954	1,018	(6%)	2%
REVENUES FROM OTHER PRODUCTS:
ANIMAL HEALTH	$1,017	$1,041	(2%)	4%	$451	$433	4%	$566	$608	(7%)	4%
CONSUMER HEALTHCARE	$780	$767	2%	6%	$388	$408	(5%)	$392	$359	9%	18%
OTHER ^(f)	$62	$54	15%	19%	$19	$19	-	$43	$35	23%	28%

(a)		Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region. Details for these regions are located on the following page.
(b)		Lipitor lost exclusivity in the U.S. in November 2011 and various other markets in 2011 and 2012. This loss of exclusivity reduced branded worldwide revenues by $1.9 billion in the third quarter of 2012, in comparison with the third quarter of 2011.
(c)		Represents direct sales under license agreement with Eisai Co., Ltd.
(d)		Includes Enbrel (in the U.S. and Canada), Aricept, Exforge, Rebif and Spiriva.
(e)		Includes sales of generic atorvastatin. All other established products is a subset of All other biopharmaceutical products.
(f)		Includes revenues generated primarily from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization.

Certain amounts and percentages may reflect rounding adjustments.


PFIZER INC. REVENUES DETAIL OF INTERNATIONAL REVENUES BY GEOGRAPHIC REGION THIRD QUARTER 2012 and 2011 (UNAUDITED) (millions of dollars)

	DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(b)				EMERGING MARKETS ^(c)

	2012	2011	% Change		2012	2011	% Change		2012	2011	% Change
			Total	Oper.			Total	Oper.			Total	Oper.
TOTAL INTERNATIONAL REVENUES	$2,976	$4,027	(26%)	(16%)	$2,529	$2,807	(10%)	(8%)	$2,844	$2,896	(2%)	7%
REVENUES FROM BIOPHARMACEUTICAL PRODUCTS - INTERNATIONAL:	$2,672	$3,723	(28%)	(18%)	$2,287	$2,567	(11%)	(10%)	$2,389	$2,438	(2%)	6%
Lipitor ^(d)	130	595	(78%)	(75%)	207	337	(39%)	(38%)	220	200	10%	14%
Lyrica	324	326	(1%)	13%	185	162	14%	17%	97	94	3%	15%
Enbrel (Outside Canada)	555	626	(11%)	1%	148	139	6%	8%	190	192	(1%)	12%
Prevnar 13/ Prevenar 13	161	192	(16%)	(5%)	63	84	(25%)	(24%)	204	276	(26%)	(28%)
Celebrex	37	46	(20%)	(9%)	119	112	6%	10%	82	80	3%	9%
Viagra	92	102	(10%)	1%	48	57	(16%)	(14%)	90	90	-	7%
Norvasc	27	38	(29%)	(14%)	150	187	(20%)	(20%)	129	120	8%	12%
Zyvox	73	78	(6%)	5%	37	38	(3%)	-	60	51	18%	27%
Sutent	103	119	(13%)	(2%)	44	42	5%	5%	65	59	10%	25%
Premarin family	2	3	(33%)	-	11	7	57%	22%	12	16	(25%)	(7%)
Genotropin	71	90	(21%)	(9%)	56	55	2%	2%	26	24	8%	16%
Xalatan/Xalacom	57	126	(55%)	(49%)	73	94	(22%)	(21%)	42	48	(13%)	(2%)
BeneFIX	63	69	(9%)	4%	33	25	32%	31%	9	8	13%	25%
Detrol/Detrol LA	29	38	(24%)	(16%)	24	25	(4%)	4%	11	14	(21%)	(14%)
Vfend	68	78	(13%)	-	42	34	24%	14%	56	59	(5%)	2%
Chantix/Champix	27	37	(27%)	(21%)	44	39	13%	18%	13	12	8%	18%
Pristiq	-	-	-	-	22	17	29%	41%	10	10	-	20%
Refacto AF/Xyntha	93	99	(6%)	6%	18	9	100%	138%	11	-	100%	*
Revatio	34	37	(8%)	6%	13	12	8%	17%	10	11	(9%)	-
Zoloft	13	17	(24%)	(18%)	67	74	(9%)	(8%)	32	33	(3%)	9%
Medrol	21	24	(13%)	(4%)	12	11	9%	9%	56	59	(5%)	-
Zosyn/Tazocin	10	15	(33%)	(20%)	3	4	(25%)	-	57	55	4%	7%
Effexor	26	48	(46%)	(38%)	18	39	(54%)	(51%)	26	26	-	12%
Geodon/Zeldox	15	18	(17%)	(11%)	4	7	(43%)	-	12	21	(43%)	(38%)
Zithromax/Zmax	11	15	(27%)	(13%)	35	37	(5%)	(3%)	40	37	8%	11%
Prevnar/Prevenar (7-valent)	-	4	(100%)	(100%)	70	94	(26%)	(27%)	11	-	100%	*
Fragmin	45	45	-	9%	18	21	(14%)	(5%)	17	20	(15%)	(5%)
Relpax	17	20	(15%)	(5%)	15	15	-	14%	4	4	-	25%
Rapamune	13	15	(13%)	-	5	4	25%	-	25	30	(17%)	(3%)
Cardura	22	30	(27%)	(14%)	31	37	(16%)	(18%)	24	24	-	8%
Aricept ^(e)	18	61	(70%)	(66%)	44	45	(2%)	5%	9	11	(18%)	(9%)
Tygacil	17	16	6%	19%	2	1	100%	100%	26	21	24%	43%
EpiPen	-	-	-	-	15	12	25%	25%	-	-	-	-
Xanax XR	22	26	(15%)	(4%)	10	12	(17%)	(8%)	21	26	(19%)	(12%)
BMP2	-	6	(100%)	(100%)	-	-	-	-	-	-	-	-
Caduet	3	4	(25%)	-	37	51	(27%)	(25%)	15	15	-	14%
Sulperazon	-	-	-	-	9	11	(18%)	(18%)	53	40	33%	32%
Diflucan	14	21	(33%)	(24%)	10	13	(23%)	(17%)	36	38	(5%)	(3%)
Dalacin/Cleocin	7	9	(22%)	(11%)	7	7	-	(14%)	20	20	-	5%
Neurontin	14	17	(18%)	(6%)	10	14	(29%)	(21%)	16	22	(27%)	(23%)
Unasyn	9	8	13%	25%	17	21	(19%)	(15%)	28	26	8%	4%
Aromasin	17	42	(60%)	(52%)	13	17	(24%)	(28%)	18	18	-	6%
Arthrotec	8	12	(33%)	(25%)	12	13	(8%)	-	2	4	(50%)	(50%)
Inspra	31	33	(6%)	9%	15	13	15%	15%	4	4	-	25%
Toviaz	17	18	(6%)	6%	3	3	-	-	3	2	50%	50%
Metaxalone/Skelaxin	-	-	-	-	-	-	-	-	-	-	-	-
Methotrexate	9	12	(25%)	(17%)	40	38	5%	8%	1	1	-	100%
Protonix	-	-	-	-	-	-	-	-	-	-	-	-
Alliance Revenue ^(f)	53	131	(60%)	(55%)	128	196	(35%)	(33%)	11	21	(48%)	(43%)
All other biopharmaceutical products	294	357	(18%)	(7%)	300	282	6%	5%	485	496	(2%)	10%
All other established products ^(g)	246	294	(16%)	(4%)	271	283	(4%)	(3%)	437	441	(1%)	10%
REVENUES FROM OTHER PRODUCTS - INTERNATIONAL:	$304	$304	-	14%	$242	$240	1%	5%	$455	$458	(1%)	9%


*		Calculation not meaningful.
(a)		Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
(b)		Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
(c)		Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.
(d)		Lipitor lost exclusivity in various international markets in 2011 and 2012. This loss of exclusivity reduced branded international revenues by $579 million in the third quarter of 2012, in comparison with the third quarter of 2011.0
(e)		Represents direct sales under license agreement with Eisai Co., Ltd.
(f)		Includes Enbrel (in Canada), Aricept, Exforge, Rebif and Spiriva.
(g)		All other established products is a subset of All other biopharmaceutical products.

Certain amounts and percentages may reflect rounding adjustments.


PFIZER INC. REVENUES NINE MONTHS 2012 and 2011 (UNAUDITED) (millions of dollars)


	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)

	2012	2011	% Change		2012	2011	% Change	2012	2011	% Change
			Total	Oper.			Total			Total	Oper.
TOTAL REVENUES	$43,918	$49,118	(11%)	(9%)	$17,303	$20,603	(16%)	$26,615	$28,515	(7%)	(2%)
REVENUES FROM BIOPHARMACEUTICAL PRODUCTS:	$38,321	$43,611	(12%)	(10%)	$14,899	$18,246	(18%)	$23,422	$25,365	(8%)	(4%)
Lipitor ^(b)	3,364	7,578	(56%)	(55%)	871	4,187	(79%)	2,493	3,391	(26%)	(25%)
Lyrica	3,026	2,695	12%	16%	1,229	1,116	10%	1,797	1,579	14%	20%
Enbrel (Outside the U.S. and Canada)	2,780	2,741	1%	8%	-	-	-	2,780	2,741	1%	8%
Prevnar 13/Prevenar 13	2,725	2,823	(3%)	(1%)	1,423	1,533	(7%)	1,302	1,290	1%	5%
Celebrex	1,969	1,856	6%	7%	1,266	1,179	7%	703	677	4%	7%
Viagra	1,498	1,458	3%	5%	822	732	12%	676	726	(7%)	(3%)
Norvasc	1,001	1,081	(7%)	(7%)	38	23	65%	963	1,058	(9%)	(9%)
Zyvox	996	965	3%	6%	490	486	1%	506	479	6%	11%
Sutent	913	870	5%	10%	255	218	17%	658	652	1%	8%
Premarin family	797	757	5%	6%	724	683	6%	73	74	(1%)	6%
Genotropin	619	654	(5%)	(2%)	150	144	4%	469	510	(8%)	(4%)
Xalatan/Xalacom	617	960	(36%)	(33%)	30	159	(81%)	587	801	(27%)	(24%)
BeneFIX	577	518	11%	14%	272	223	22%	305	295	3%	8%
Detrol/Detrol LA	576	668	(14%)	(12%)	362	422	(14%)	214	246	(13%)	(10%)
Vfend	543	558	(3%)	1%	64	64	-	479	494	(3%)	1%
Chantix/Champix	496	545	(9%)	(7%)	234	248	(6%)	262	297	(12%)	(9%)
Pristiq	461	422	9%	10%	365	348	5%	96	74	30%	36%
Refacto AF/Xyntha	420	380	11%	16%	79	75	5%	341	305	12%	19%
Revatio	414	393	5%	8%	250	229	9%	164	164	-	7%
Zoloft	398	420	(5%)	(4%)	49	46	7%	349	374	(7%)	(5%)
Medrol	388	383	1%	4%	105	116	(9%)	283	267	6%	9%
Zosyn/Tazocin	378	490	(23%)	(21%)	175	267	(34%)	203	223	(9%)	(5%)
Effexor	342	537	(36%)	(34%)	102	207	(51%)	240	330	(27%)	(24%)
Geodon/Zeldox	322	753	(57%)	(56%)	218	627	(65%)	104	126	(17%)	(10%)
Zithromax/Zmax	318	335	(5%)	(4%)	9	17	(47%)	309	318	(3%)	(2%)
Prevnar/Prevenar (7-valent)	303	406	(25%)	(22%)	-	-	-	303	406	(25%)	(22%)
Fragmin	283	283	-	6%	36	32	13%	247	251	(2%)	5%
Relpax	266	250	6%	8%	160	142	13%	106	108	(2%)	4%
Rapamune	259	285	(9%)	(6%)	140	139	1%	119	146	(18%)	(13%)
Cardura	254	289	(12%)	(9%)	4	4	-	250	285	(12%)	(9%)
Aricept ^(c)	249	335	(26%)	(22%)	-	-	-	249	335	(26%)	(22%)
Tygacil	249	224	11%	16%	115	112	3%	134	112	20%	28%
EpiPen ^(d)	217	160	36%	36%	182	133	37%	35	27	30%	33%
Xanax XR	203	232	(13%)	(7%)	38	41	(7%)	165	191	(14%)	(7%)
BMP2	192	277	(31%)	(31%)	192	260	(26%)	-	17	(100%)	(98%)
Caduet	191	435	(56%)	(55%)	26	235	(89%)	165	200	(18%)	(16%)
Sulperazon	191	155	23%	22%	-	-	-	191	155	23%	22%
Diflucan	185	201	(8%)	(5%)	4	3	33%	181	198	(9%)	(5%)
Dalacin/Cleocin	176	139	27%	31%	72	35	106%	104	104	-	5%
Neurontin	172	222	(23%)	(19%)	37	51	(27%)	135	171	(21%)	(17%)
Unasyn	165	172	(4%)	(2%)	2	4	(50%)	163	168	(3%)	(1%)
Aromasin	162	294	(45%)	(43%)	10	53	(81%)	152	241	(37%)	(34%)
Arthrotec	159	182	(13%)	(11%)	90	96	(6%)	69	86	(20%)	(15%)
Inspra	156	142	10%	16%	4	3	33%	152	139	9%	16%
Toviaz	150	137	9%	13%	82	72	14%	68	65	5%	11%
Metaxalone/Skelaxin ^(d)	149	145	3%	2%	149	145	3%	-	-	-	-
Methotrexate	148	133	11%	11%	-	-	-	148	133	11%	11%
Protonix	140	168	(17%)	(17%)	140	168	(17%)	-	-	-	-
Alliance Revenue ^(e)	2,577	2,678	(4%)	(3%)	1,908	1,628	17%	669	1,050	(36%)	(35%)
All other biopharmaceutical products	5,187	4,827	7%	11%	1,926	1,541	25%	3,261	3,286	(1%)	5%
All other established products ^(f)	4,509	4,207	7%	11%	1,633	1,287	27%	2,876	2,920	(2%)	4%
REVENUES FROM OTHER PRODUCTS:
ANIMAL HEALTH	$3,128	$3,078	2%	6%	$1,289	$1,205	7%	$1,839	$1,873	(2%)	5%
CONSUMER HEALTHCARE	$2,276	$2,218	3%	5%	$1,054	$1,087	(3%)	$1,222	$1,131	8%	13%
OTHER ^(g)	$193	$211	(9%)	(8%)	$61	$65	(6%)	$132	$146	(10%)	(7%)


(a)		Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region. Details for these regions are located on the following page.
(b)		Lipitor lost exclusivity in the U.S. in November 2011 and various other markets in 2011 and 2012. This loss of exclusivity reduced branded worldwide revenues by $4.2 billion in the first nine months of 2012, in comparison with the first nine months of 2011.
(c)		Represents direct sales under license agreement with Eisai Co., Ltd.
(d)		Legacy King product. King's operations are included in our financial statements commencing from the acquisition date of January 31, 2011.
(e)		Includes Enbrel (in the U.S. and Canada), Aricept, Exforge, Rebif and Spiriva.
(f)		Includes sales of generic atorvastatin. All other established products is a subset of All other biopharmaceutical products.
(g)		Includes revenues generated primarily from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization.

Certain amounts and percentages may reflect rounding adjustments.


PFIZER INC. REVENUES DETAIL OF INTERNATIONAL REVENUES BY GEOGRAPHIC REGION NINE MONTHS 2012 and 2011 (UNAUDITED) (millions of dollars)


	DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(b)				EMERGING MARKETS ^(c)

	2012	2011	% Change		2012	2011	% Change		2012	2011	% Change
			Total	Oper.			Total	Oper.			Total	Oper.
TOTAL INTERNATIONAL REVENUES	$10,025	$12,078	(17%)	(11%)	$7,830	$7,974	(2%)	(2%)	$8,760	$8,463	4%	10%
REVENUES FROM BIOPHARMACEUTICAL PRODUCTS - INTERNATIONAL:	$9,026	$11,064	(18%)	(12%)	$7,088	$7,270	(3%)	(3%)	$7,308	$7,031	4%	10%
Lipitor ^(d)	1,042	1,804	(42%)	(39%)	777	955	(19%)	(20%)	674	632	7%	9%
Lyrica	955	931	3%	11%	526	381	38%	38%	316	267	18%	26%
Enbrel (Outside Canada)	1,691	1,758	(4%)	4%	451	391	15%	13%	638	592	8%	17%
Prevnar 13/ Prevenar 13	496	545	(9%)	(2%)	201	171	18%	19%	605	574	5%	8%
Celebrex	121	134	(10%)	(2%)	341	307	11%	12%	241	236	2%	7%
Viagra	267	296	(10%)	(4%)	152	158	(4%)	(3%)	257	272	(6%)	(1%)
Norvasc	91	127	(28%)	(22%)	488	575	(15%)	(17%)	384	356	8%	10%
Zyvox	224	229	(2%)	6%	115	108	6%	6%	167	142	18%	25%
Sutent	325	353	(8%)	(1%)	128	122	5%	5%	205	177	16%	26%
Premarin family	7	8	(13%)	(13%)	27	24	13%	12%	39	42	(7%)	2%
Genotropin	224	267	(16%)	(10%)	166	162	2%	1%	79	81	(2%)	5%
Xalatan/Xalacom	220	385	(43%)	(39%)	232	270	(14%)	(15%)	135	146	(8%)	1%
BeneFIX	182	193	(6%)	1%	98	82	20%	18%	25	20	25%	30%
Detrol/Detrol LA	97	119	(18%)	(14%)	74	82	(10%)	(9%)	43	45	(4%)	2%
Vfend	203	226	(10%)	(3%)	118	108	9%	5%	158	160	(1%)	4%
Chantix/Champix	94	134	(30%)	(27%)	132	124	6%	6%	36	39	(8%)	3%
Pristiq	-	-	-	-	62	48	29%	33%	34	26	31%	42%
Refacto AF/Xyntha	274	279	(2%)	5%	44	25	76%	83%	23	1	*	*
Revatio	100	105	(5%)	3%	40	34	18%	18%	24	25	(4%)	8%
Zoloft	44	61	(28%)	(23%)	207	217	(5%)	(6%)	98	96	2%	8%
Medrol	70	78	(10%)	(3%)	36	35	3%	-	177	154	15%	18%
Zosyn/Tazocin	37	49	(24%)	(18%)	11	11	-	-	155	163	(5%)	(1%)
Effexor	84	141	(40%)	(35%)	80	114	(30%)	(30%)	76	75	1%	7%
Geodon/Zeldox	46	58	(21%)	(14%)	15	17	(12%)	-	43	51	(16%)	(8%)
Zithromax/Zmax	45	61	(26%)	(20%)	134	131	2%	1%	130	126	3%	5%
Prevnar/Prevenar (7-valent)	-	22	(100%)	(100%)	258	277	(7%)	(10%)	45	107	(58%)	(44%)
Fragmin	135	132	2%	8%	58	57	2%	9%	54	62	(13%)	(5%)
Relpax	50	56	(11%)	(4%)	43	40	8%	8%	13	12	8%	17%
Rapamune	39	45	(13%)	(7%)	13	13	-	-	67	88	(24%)	(17%)
Cardura	72	94	(23%)	(18%)	102	116	(12%)	(14%)	76	75	1%	7%
Aricept ^(e)	93	171	(46%)	(42%)	126	125	1%	5%	30	39	(23%)	(15%)
Tygacil	50	49	2%	10%	5	4	25%	25%	79	59	34%	44%
EpiPen ^(f)	-	-	-	-	35	27	30%	33%	-	-	-	-
Xanax XR	65	80	(19%)	(11%)	33	36	(8%)	(8%)	67	75	(11%)	(1%)
BMP2	-	17	(100%)	(100%)	-	-	-	-	-	-	-	-
Caduet	10	13	(23%)	(15%)	108	143	(24%)	(24%)	47	44	7%	11%
Sulperazon	-	-	-	-	27	32	(16%)	(19%)	164	123	33%	33%
Diflucan	47	59	(20%)	(14%)	30	35	(14%)	(14%)	104	104	-	3%
Dalacin/Cleocin	23	26	(12%)	(4%)	21	19	11%	5%	60	59	2%	10%
Neurontin	45	58	(22%)	(17%)	31	42	(26%)	(24%)	59	71	(17%)	(11%)
Unasyn	27	26	4%	12%	55	61	(10%)	(10%)	81	81	-	1%
Aromasin	57	142	(60%)	(56%)	41	51	(20%)	(22%)	54	48	13%	17%
Arthrotec	26	37	(30%)	(24%)	35	37	(5%)	(3%)	8	12	(33%)	(25%)
Inspra	96	92	4%	13%	44	37	19%	16%	12	10	20%	30%
Toviaz	54	52	4%	12%	7	7	-	17%	7	6	17%	17%
Metaxalone/Skelaxin ^(f)	-	-	-	-	-	-	-	-	-	-	-	-
Methotrexate	28	33	(15%)	(9%)	117	98	19%	16%	3	2	50%	50%
Protonix	-	-	-	-	-	-	-	-	-	-	-	-
Alliance Revenue ^(g)	204	433	(53%)	(50%)	414	557	(26%)	(26%)	51	60	(15%)	(5%)
All other biopharmaceutical products	966	1,086	(11%)	(4%)	830	804	3%	2%	1,465	1,396	5%	13%
All other established products ^(h)	769	883	(13%)	(6%)	786	806	(2%)	(3%)	1,321	1,231	7%	16%
REVENUES FROM OTHER PRODUCTS - INTERNATIONAL:	$999	$1,014	(1%)	6%	$742	$704	5%	7%	$1,452	$1,432	1%	8%


*		Calculation not meaningful.
(a)		Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
(b)		Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
(c)		Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.
(d)		Lipitor lost exclusivity in various international markets in 2011 and 2012. This loss of exclusivity reduced branded international revenues by $914 million in the first nine months of 2012, in comparison with the first nine months of 2011.
(e)		Represents direct sales under license agreement with Eisai Co., Ltd.
(f)		Legacy King product. King's operations are included in our financial statements commencing from the acquisition date of January 31, 2011.
(g)		Includes Enbrel (in Canada), Aricept, Exforge, Rebif and Spiriva.
(h)		All other established products is a subset of All other biopharmaceutical products.

Certain amounts and percentages may reflect rounding adjustments.

PFIZER INC. SUPPLEMENTAL INFORMATION

1. Change in Reported Cost of Sales

Reported cost of sales decreased 22% in both the third quarter and in the first nine months of 2012, compared to the same periods in 2011. The decreases were primarily due to a decline in revenues reflecting reduced manufacturing volumes related to products that lost exclusivity in various markets. The decreases were also due to lower purchase accounting adjustments in 2012, lower costs related to our cost-reduction and productivity initiatives, as well as the benefits generated from the ongoing productivity initiatives to streamline the manufacturing network, and favorable foreign exchange of 8% for the third quarter of 2012 and 7% for the first nine months of 2012. The decreases were partially offset by an unfavorable impact caused by a shift in geographic and business mix.

« First ‹ Previous 1 2 3 4 5 6 7 8 Next › Last »

Select the service that is right for you!

COMPARE ALL SERVICES

Action Alerts PLUS

TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Real Money

TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:

Jim Cramer + 20 Wall Street pros
Intraday commentary & news
Real-time trading forum
Actionable trade ideas

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:

100+ monthly options trading ideas
Actionable options commentary & news
Real-time trading community
Options TV

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.